JP2020521445A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020521445A5 JP2020521445A5 JP2019564464A JP2019564464A JP2020521445A5 JP 2020521445 A5 JP2020521445 A5 JP 2020521445A5 JP 2019564464 A JP2019564464 A JP 2019564464A JP 2019564464 A JP2019564464 A JP 2019564464A JP 2020521445 A5 JP2020521445 A5 JP 2020521445A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- peptide
- pharmaceutical composition
- composition according
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 42
- 239000008194 pharmaceutical composition Substances 0.000 claims description 26
- 230000004048 modification Effects 0.000 claims description 12
- 238000012986 modification Methods 0.000 claims description 12
- 208000035473 Communicable disease Diseases 0.000 claims description 11
- 102000039446 nucleic acids Human genes 0.000 claims description 10
- 108020004707 nucleic acids Proteins 0.000 claims description 10
- 150000007523 nucleic acids Chemical class 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 208000035475 disorder Diseases 0.000 claims description 9
- 230000003463 hyperproliferative effect Effects 0.000 claims description 9
- 206010040047 Sepsis Diseases 0.000 claims description 7
- 231100000444 skin lesion Toxicity 0.000 claims description 7
- 206010040882 skin lesion Diseases 0.000 claims description 7
- 230000002087 whitening effect Effects 0.000 claims description 7
- 101000755953 Bacillus subtilis (strain 168) Ribosome maturation factor RimP Proteins 0.000 claims description 6
- 239000013543 active substance Substances 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 6
- 244000309459 oncolytic virus Species 0.000 claims description 6
- 102220277134 rs776745497 Human genes 0.000 claims description 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 5
- 210000004027 cell Anatomy 0.000 claims description 5
- 238000002255 vaccination Methods 0.000 claims description 5
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 claims description 4
- 101710168331 ALK tyrosine kinase receptor Proteins 0.000 claims description 4
- 101150051188 Adora2a gene Proteins 0.000 claims description 4
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 4
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 4
- 102000003964 Histone deacetylase Human genes 0.000 claims description 4
- 108090000353 Histone deacetylase Proteins 0.000 claims description 4
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 4
- 108060003951 Immunoglobulin Proteins 0.000 claims description 4
- 102000053646 Inducible T-Cell Co-Stimulator Human genes 0.000 claims description 4
- 108700013161 Inducible T-Cell Co-Stimulator Proteins 0.000 claims description 4
- 102000002698 KIR Receptors Human genes 0.000 claims description 4
- 108010043610 KIR Receptors Proteins 0.000 claims description 4
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 239000000556 agonist Substances 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 102000018358 immunoglobulin Human genes 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 claims description 4
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 3
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 3
- 230000006044 T cell activation Effects 0.000 claims description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- YIMATHOGWXZHFX-WCTZXXKLSA-N (2r,3r,4r,5r)-5-(hydroxymethyl)-3-(2-methoxyethoxy)oxolane-2,4-diol Chemical compound COCCO[C@H]1[C@H](O)O[C@H](CO)[C@H]1O YIMATHOGWXZHFX-WCTZXXKLSA-N 0.000 claims description 2
- TXQAZWIBPGKHOX-UHFFFAOYSA-N 1H-indol-3-amine Chemical compound C1=CC=C2C(N)=CNC2=C1 TXQAZWIBPGKHOX-UHFFFAOYSA-N 0.000 claims description 2
- 101710144268 B- and T-lymphocyte attenuator Proteins 0.000 claims description 2
- 101150013553 CD40 gene Proteins 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 150000008574 D-amino acids Chemical class 0.000 claims description 2
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims description 2
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 2
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 2
- 150000008575 L-amino acids Chemical class 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 2
- 229920002807 Thiomer Polymers 0.000 claims description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 2
- 108091008605 VEGF receptors Proteins 0.000 claims description 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 2
- 230000021736 acetylation Effects 0.000 claims description 2
- 238000006640 acetylation reaction Methods 0.000 claims description 2
- 239000002998 adhesive polymer Substances 0.000 claims description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 239000005557 antagonist Substances 0.000 claims description 2
- 230000000903 blocking effect Effects 0.000 claims description 2
- 210000004899 c-terminal region Anatomy 0.000 claims description 2
- 238000009566 cancer vaccine Methods 0.000 claims description 2
- 229940022399 cancer vaccine Drugs 0.000 claims description 2
- 238000002659 cell therapy Methods 0.000 claims description 2
- 239000002299 complementary DNA Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 239000003862 glucocorticoid Substances 0.000 claims description 2
- 208000002672 hepatitis B Diseases 0.000 claims description 2
- 239000000017 hydrogel Substances 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 201000004792 malaria Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 239000011859 microparticle Substances 0.000 claims description 2
- 239000007908 nanoemulsion Substances 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 101710135378 pH 6 antigen Proteins 0.000 claims description 2
- LQRJAEQXMSMEDP-XCHBZYMASA-N peptide a Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)NCCCC[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)C(\NC(=O)[C@@H](CCCCN)NC(=O)CNC(C)=O)=C/C=1C=CC=CC=1)C(N)=O)C(=O)C(\NC(=O)[C@@H](CCCCN)NC(=O)CNC(C)=O)=C\C1=CC=CC=C1 LQRJAEQXMSMEDP-XCHBZYMASA-N 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 239000002047 solid lipid nanoparticle Substances 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 2
- 102000003390 tumor necrosis factor Human genes 0.000 claims description 2
- 229960005486 vaccine Drugs 0.000 claims description 2
- 239000012646 vaccine adjuvant Substances 0.000 claims description 2
- 229940124931 vaccine adjuvant Drugs 0.000 claims description 2
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 1
- 230000009435 amidation Effects 0.000 claims 1
- 238000007112 amidation reaction Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762510900P | 2017-05-25 | 2017-05-25 | |
| US62/510,900 | 2017-05-25 | ||
| PCT/US2018/034625 WO2018218137A1 (en) | 2017-05-25 | 2018-05-25 | Pd-1 and ctla-4 dual inhibitor peptides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020521445A JP2020521445A (ja) | 2020-07-27 |
| JP2020521445A5 true JP2020521445A5 (https=) | 2021-05-13 |
| JP7187486B2 JP7187486B2 (ja) | 2022-12-12 |
Family
ID=62705685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019564464A Active JP7187486B2 (ja) | 2017-05-25 | 2018-05-25 | Ｐｄ－１およびｃｔｌａ－４二重インヒビターペプチド |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11033622B2 (https=) |
| EP (1) | EP3630807B1 (https=) |
| JP (1) | JP7187486B2 (https=) |
| AU (1) | AU2018273958B2 (https=) |
| CA (1) | CA3064023A1 (https=) |
| ES (1) | ES3041991T3 (https=) |
| WO (1) | WO2018218137A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| US10799555B2 (en) | 2016-09-15 | 2020-10-13 | Leidos, Inc. | PD-1 peptide inhibitors |
| WO2018218137A1 (en) | 2017-05-25 | 2018-11-29 | Leidos, Inc. | Pd-1 and ctla-4 dual inhibitor peptides |
| JP2022516318A (ja) * | 2019-01-04 | 2022-02-25 | オンコラス， インコーポレイテッド | カプセル化ポリヌクレオチド及び使用方法 |
| WO2020247830A1 (en) * | 2019-06-06 | 2020-12-10 | Huya Bioscience International, Llc | Triplet therapies of hdac inhibitors, pd-l1 and/or pd-1 inhibitors, and ctla-4 inhibitors |
| CA3185657A1 (en) * | 2020-06-04 | 2021-12-09 | Leidos, Inc. | Immunomodulatory compounds |
| EP4225444A1 (en) * | 2020-10-12 | 2023-08-16 | Leidos, Inc. | Immunomodulatory peptides |
| CN112745384A (zh) * | 2021-01-15 | 2021-05-04 | 新乡学院 | 猪pd-l14qn-gf表位多肽及其应用 |
| JP2024505274A (ja) * | 2021-02-02 | 2024-02-05 | ゲオバックス インコーポレイテッド | ワクチン接種中のｔ細胞プライミングの強化において使用されるウイルスコンストラクト |
| CN112724197A (zh) * | 2021-02-03 | 2021-04-30 | 河南大学 | 一种免疫治疗中用于阻断pdl1的7肽 |
| CN116262137A (zh) * | 2021-12-14 | 2023-06-16 | 四川大学 | 一种同时杀伤肿瘤和改善免疫微环境的抗肿瘤联合用药物 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20000022459A (ko) * | 1996-07-01 | 2000-04-25 | 칼튼 제이. 에이블 | 밤나방과 해충에 대해 활성적인 바실루스 츄린겐시스 독소 |
| JP2001523958A (ja) * | 1997-03-21 | 2001-11-27 | ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド | 免疫療法のｃｔｌａ−４結合ペプチド |
| JP2002513811A (ja) | 1998-05-06 | 2002-05-14 | ファルマシア・アンド・アップジョン・カンパニー | 非−ヒト脊椎動物への、非−ヒト脊椎動物のペプチドホルモンまたはサイトカインをコードする裸のｄｎａまたは裸のｒｎａの導入 |
| CA2541006C (en) | 2003-10-03 | 2015-02-17 | Brigham And Women's Hospital | Tim-3 polypeptides |
| US10668119B2 (en) | 2005-08-01 | 2020-06-02 | Virocure, Inc. | Attenuated reovirus |
| EP2201120B1 (en) | 2007-09-21 | 2013-12-25 | Cadila Healthcare Limited | Gcsf fusion protein systems suitable for high expression of peptides |
| US20130202623A1 (en) | 2010-02-16 | 2013-08-08 | Nicolas Chomont | Pd-1 modulation and uses thereof for modulating hiv replication |
| MX2012009632A (es) * | 2010-02-18 | 2012-09-28 | Athenix Corp | Genes delta-endotoxinicos axmi221z, axmi222z, axmi223z, axmi224z, axmi225z y metodos para su uso. |
| MX374075B (es) | 2010-03-26 | 2025-03-05 | Dartmouth College | Proteina mediadora de celula t regulatoria vista, agentes de enlace de vista y uso de los mismos. |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| US9845362B2 (en) | 2010-10-08 | 2017-12-19 | The University Of North Carolina At Charlotte | Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same |
| US20130267515A1 (en) | 2010-10-26 | 2013-10-10 | Alberta Health Services | Combination comprising an atp analog and an adenosine receptor antagonist or a nucleobase/nucleoside analog for the treatment of cancer |
| CN102085735B (zh) | 2010-11-09 | 2013-03-27 | 浙江大东南包装股份有限公司 | 一种多功能bopp烟用包装膜及其制造方法 |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| WO2012116714A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in elderly patients |
| WO2012168944A1 (en) | 2011-06-08 | 2012-12-13 | Aurigene Discovery Technologies Limited | Therapeutic compounds for immunomodulation |
| WO2013043569A1 (en) * | 2011-09-20 | 2013-03-28 | Vical Incorporated | Synergistic anti-tumor efficacy using alloantigen combination immunotherapy |
| EP2583975A1 (en) | 2011-10-21 | 2013-04-24 | Heinrich-Heine-Universität Düsseldorf | Agents and methods for the expression and secretion of peptides and proteins |
| WO2013132317A1 (en) | 2012-03-07 | 2013-09-12 | Aurigene Discovery Technologies Limited | Peptidomimetic compounds as immunomodulators |
| CA2868408A1 (en) | 2012-03-29 | 2013-10-03 | Aurigene Discovery Technologies Limited | Immunomodulating cyclic compounds from the bc loop of human pd1 |
| US9381244B2 (en) | 2012-09-07 | 2016-07-05 | King's College London | VISTA modulators for diagnosis and treatment of cancer |
| US20150250837A1 (en) | 2012-09-20 | 2015-09-10 | Morningside Technology Ventures Ltd. | Oncolytic virus encoding pd-1 binding agents and uses of the same |
| PL2904011T3 (pl) | 2012-10-02 | 2018-01-31 | Bristol Myers Squibb Co | Połączenie przeciwciał anty-kir i przeciwciał anty-pd-1 w leczeniu raka |
| US9974845B2 (en) | 2013-02-22 | 2018-05-22 | Curevac Ag | Combination of vaccination and inhibition of the PD-1 pathway |
| US9320706B2 (en) | 2013-03-13 | 2016-04-26 | Transdermal Biotechnology, Inc. | Immune modulation using peptides and other compositions |
| US9295647B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Systems and methods for delivery of peptides |
| EP2792686A1 (en) | 2013-04-17 | 2014-10-22 | Heinrich-Heine-Universität Düsseldorf | Methods for the expression of peptides and proteins |
| US20160145355A1 (en) | 2013-06-24 | 2016-05-26 | Biomed Valley Discoveries, Inc. | Bispecific antibodies |
| KR102354389B1 (ko) * | 2013-08-21 | 2022-01-20 | 큐어백 아게 | Rna―암호화된 단백질의 발현을 증가시키는 방법 |
| CN104072615B (zh) | 2014-01-26 | 2016-08-24 | 中国人民解放军军事医学科学院基础医学研究所 | 一种能阻断Tim-3信号通路的人Tim-3融合蛋白 |
| HUE045065T2 (hu) | 2014-01-31 | 2019-12-30 | Novartis Ag | TIM-3 antitest molekulák és felhasználásaik |
| US10899840B2 (en) | 2014-02-04 | 2021-01-26 | Pfizer Inc. | Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer |
| SG11201606428UA (en) | 2014-02-04 | 2016-09-29 | Incyte Corp | Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer |
| BR102014014502B1 (pt) | 2014-06-13 | 2020-09-15 | Ouro Fino Saúde Animal Ltda | Vetor de expressão |
| ES2833425T3 (es) | 2014-07-16 | 2021-06-15 | Roussy Inst Gustave | Combinación de virus oncolítico con moduladores de punto de control inmunitario |
| RU2696312C2 (ru) | 2014-07-16 | 2019-08-01 | Трансген Са | Онколитический вирус для экспрессии модуляторов иммунологических контрольных точек |
| US10695426B2 (en) | 2014-08-25 | 2020-06-30 | Pfizer Inc. | Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer |
| US10016480B2 (en) | 2014-10-14 | 2018-07-10 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Peptide-based methods for treating pancreatic cancer |
| BR112017007765B1 (pt) | 2014-10-14 | 2023-10-03 | Halozyme, Inc | Composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo |
| GB201504502D0 (en) | 2015-03-17 | 2015-04-29 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers |
| CA2994241A1 (en) * | 2015-07-31 | 2017-02-09 | University Of Florida Research Foundation, Inc. | Hematopoietic stem cells in combinatorial therapy with immune checkpoint inhibitors against cancer |
| US9957325B2 (en) | 2015-10-13 | 2018-05-01 | Formurex, Inc. | Synthetic antibody mimic peptides |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| AU2017290828A1 (en) | 2016-06-30 | 2019-01-24 | Virogin Biotech Canada Ltd | Pseudotyped oncolytic viral delivery of therapeutic polypeptides |
| US10098950B2 (en) | 2016-09-15 | 2018-10-16 | Leidos, Inc. | PD-1 Peptide Inhibitors |
| US10799555B2 (en) | 2016-09-15 | 2020-10-13 | Leidos, Inc. | PD-1 peptide inhibitors |
| WO2018218137A1 (en) | 2017-05-25 | 2018-11-29 | Leidos, Inc. | Pd-1 and ctla-4 dual inhibitor peptides |
| CN107383174B (zh) | 2017-08-21 | 2019-01-18 | 生工生物工程（上海）股份有限公司 | 一种能与pd-1特异性结合的肿瘤抑制肽及其用途 |
-
2018
- 2018-05-25 WO PCT/US2018/034625 patent/WO2018218137A1/en not_active Ceased
- 2018-05-25 EP EP18733407.3A patent/EP3630807B1/en active Active
- 2018-05-25 ES ES18733407T patent/ES3041991T3/es active Active
- 2018-05-25 US US15/989,750 patent/US11033622B2/en active Active
- 2018-05-25 CA CA3064023A patent/CA3064023A1/en active Pending
- 2018-05-25 JP JP2019564464A patent/JP7187486B2/ja active Active
- 2018-05-25 AU AU2018273958A patent/AU2018273958B2/en active Active
-
2021
- 2021-05-12 US US17/317,985 patent/US12370258B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020521445A5 (https=) | ||
| Martinsen et al. | The use of toll-like receptor agonists in HIV-1 cure strategies | |
| JP7187486B2 (ja) | Ｐｄ－１およびｃｔｌａ－４二重インヒビターペプチド | |
| JP7284718B2 (ja) | Ｔ細胞の機能を調節するためのアンチセンスオリゴヌクレオチド | |
| US11186825B2 (en) | Compositions and methods for evaluating and modulating immune responses by detecting and targeting POU2AF1 | |
| EP3368689B1 (en) | Composition for modulating immune responses by use of immune cell gene signature | |
| JP2022533711A5 (https=) | ||
| US11180730B2 (en) | Compositions and methods for evaluating and modulating immune responses by detecting and targeting GATA3 | |
| JP2021523110A (ja) | 遺伝子発現のためのナノ粒子及びその使用 | |
| ES2955408T3 (es) | Nucleasas modificadas genéticamente optimizadas que tienen especificidad para el gen de la región constante alfa del receptor de linfocitos t humanos | |
| US20190255107A1 (en) | Modulation of novel immune checkpoint targets | |
| US20190262399A1 (en) | Compositions and methods for evaluating and modulating immune responses | |
| US11931409B2 (en) | Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids | |
| WO2018067991A1 (en) | Modulation of novel immune checkpoint targets | |
| CN109121413A (zh) | 使用靶向核酸纳米载体编程治疗性细胞的组合物和方法 | |
| US12195746B2 (en) | Compositions and processes for targeted delivery, expression and modulation of coding ribonucleic acids in tissue | |
| US20200376142A1 (en) | Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids | |
| JP2022190026A (ja) | Ｐｄ－１ペプチド阻害剤 | |
| JP2023536466A5 (https=) | ||
| JP2023548662A5 (https=) | ||
| WO2024133517A1 (en) | Methods for macrophage polarization | |
| JP2023548662A (ja) | 免疫調節性ペプチド | |
| CN116615207A (zh) | 经修饰的免疫细胞 | |
| HK40099663A (zh) | 用於治疗癌症的治疗性rna | |
| HK40083636B (zh) | 用於编码核糖核酸的器官保护性表达和调节的组合物及方法 |